Menu

Markets

Research

News

Learn

AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Vaxart, Inc. VXRT

Full chart Compare
Set alert

Price alert · VXRT

All alert types
0.37 USD 0.00 (-1.05%)

Nov 9, 2026, 3:57 PM EST

0.366 Day range 0.391
0.33 52-week range 0.84
YTD
+4.60%
1 year
-3.66%

Discussion (1070)

Sign in to join the discussion

Michael Megidish VXRT 5 years ago #441

I told my group that "Understanding the risks of buying a company with only Phase 1 data that has not been fully evaluated by the scientific and medical communities, we could start new positions between $9 and $11."

Their data may not impress scientists right now, but I'm betting they will still get funding to proceed with the next phases. And the potential is intriguing for at least two reasons besides the possibility of a COVID pill.

First, if successful, they will be targeting a unique opportunity as the only "mucosal" vaccine after Merck recently abandoned their attempts. According to some doctors, novel coronavirus is a pathogen of a mucosal organ, different than those viruses that attack systemic organs. Current vaccines are systemic, and can only reduce disease severity.

Secondly, if successful, a pill for COVID could be room-temperature stable and not require extensive cold-chain technologies.

Why own more than one vaccine stock? Because the demand outstrips supply right now, plus countries want differentiated platforms and technology.

Nader S VXRT 5 years ago #444

Bad PR IgA is a neutralizing antibody, that is in the mucosa.

Michael Megidish VXRT 5 years ago #445

“Vaxart nonetheless be remains confident that its tablet will not only be able to treat the coronavirus but also handle the emerging new strains of the virus”

“Our Phase I results highlight the importance of our differentiated vaccine design, as they suggest VXA-CoV2-1 could have broad activity against existing and future coronavirus strains," Chief Executive Andrei Floroiu said in a statement.

Michael Megidish VXRT 5 years ago #446

Phase 1 was successful!
Phase 2 will start in Q1 (says Dr tucker on the webinar).
Can’t understand this oversell.
Holding long

Nader S VXRT 5 years ago #447

The company said it is still determining if this will be a single or two-dose regimen.

A phase two study is expected "in the next couple of months," Tucker said. In its "most accelerated timeline," the company expects phase two and phase three studies to be completed by early 2022.